Nasdaq

Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China

SHANGHAI, CHINA, Oct 10, 2022 - (ACN Newswire) - - Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, ...
The Manila Times

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney ...

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progressionA Phase 2 proof-of-concept ...
Business Wire

Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017

Navitor announced lead candidate NV-5138, activator of mTORC1 for treatment-resistant depression, based on data presented at Soc. for Neuroscience.
BioWorld

NS-041, a novel KCNQ2/3 activator for the treatment of epilepsy, presented at ACS meeting

Voltage-gated potassium channels (KCNQ) control neural excitability and their dysfunction leads to neuronal channelopathies frequently related to distinct types of epilepsy ranging from benign forms ...